Since IL-10 is regarded as an anti-inflammatory cytokine and can control the Th17 prevalence [52–54], the maintenance of immune homeostasis of Th17 cells and Treg cells may be a key target for the treatment of IBD. Here, IL10 is linked to inflammatory bowel disease.